Otsuka Triumphs In Abilify Patent Litigation

Law360, New York (November 15, 2010, 6:17 PM EST) -- A federal judge handed Otsuka Pharmaceutical Co. Ltd. a victory Monday in its bid to keep a slew of companies, including Teva Pharmaceutical Industries Ltd., Apotex Inc. and Sandoz Inc., from producing generic versions of its blockbuster schizophrenia drug Abilify.

Judge Mary L. Cooper of the U.S. District Court for the District of New Jersey ruled that the patent covering Abilify is valid and enforceable and enjoined the defendants from marketing their copycat versions of the drug until Otsuka's patent expires April 20, 2015.

Abilify is...
To view the full article, register now.